PRACTICAL PROBLEMS OF COMPARATOR SELECTION TO ASSESS COST-EFFECTIVENESS OF NEW DRUGS FOR REIMBURSEMENT DECISION- A QUALITATIVE STUDY IN SOUTH KOREA

Author(s)

Kang H1, Lee H1, Cho H2
1Yonsei University, Incheon, South Korea, 2Yonsei University, College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Incheon, South Korea

OBJECTIVES: Under the positive drug listing system, pharmaceutical companies in Korea are required to provide cost-effectiveness (CE) evidence of newly approved drugs for listing on the National Health Insurance (NHI) drug formulary. It has been argued that selection criteria of comparator treatments suggested by the CE guideline are too limited and unrealistic to conduct a valid CE assessment. Therefore, our study was conducted to investigate types of practical problems in comparator selection in order to improve the validity of CE analysis. METHODS: We conducted focus group interviews (FGI) with experts working in research-based drug companies, charged of submitting CE evidence of their products to NHI. Each participant received an interview question via an e-mail beforehand and presented their opinions at round-table discussion.  RESULTS: Examples of the problems associated with selecting appropriate comparators identified from FGI are as follows: drugs with the same indication, but therapeutically nonequivalent, were used as comparators ; there is no guidance on whether to include off-label drugs as comparators; when off-patent products were selected as comparators, the price of the new drug was compared with the price of generic products rather than the initial price of the original products set during the patent period; it is difficult to obtain reliable market share data needed for selecting a comparator; and the best supportive care was selected as a comparator when there’s no appropriate treatment alternatives.  CONCLUSIONS: We expect that the results of our investigation would contribute to improve the quality of CE guidelines in South Korea as well as other countries, and to improve assessment of the true value of pharmaceutical intervention.

Conference/Value in Health Info

2015-05, ISPOR 2015, Philadelphia, PA, USA

Value in Health, Vol. 18, No. 3 (May 2015)

Code

PHP150

Topic

Health Technology Assessment

Topic Subcategory

Decision & Deliberative Processes

Disease

Multiple Diseases

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×